Frederic Tremblay, Ph.D.
Vice President, Head of In Vivo Programs
Fred is Vice President, Head of In Vivo Programs at Chroma Medicine. He also serves as an Editorial Board member of the American Journal of Physiology: Endocrinology and Metabolism. Before joining Chroma, Fred was a Scientific Director in the Gastroenterology Drug Discovery Unit at Takeda leading external research collaboration projects focused on liver diseases. Previously, Fred spent 5 years at Alnylam where he worked on various GalNAc-conjugated siRNA programs and led the preclinical development of ALN-HSD, an RNAi therapeutic that is now in Phase 2 clinical trial for the treatment of NASH. Fred also held various roles at Wyeth, Pfizer, and Ember Therapeutics. Fred received his B.S. in Food Science and Technology and Ph.D. in Physiology and Endocrinology from Laval University in Quebec, Canada.